1 Change in IRLS severity scale score |
7 |
345 |
Mean Difference (IV, Random, 95% CI) |
‐3.78 [‐6.25, ‐1.31] |
2 Change in any measure of restlessness |
8 |
370 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐1.26, ‐0.23] |
2.1 New Subgroup |
8 |
370 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐1.26, ‐0.23] |
3 Restlessness, Subgroup ‐ renal disease |
8 |
370 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐1.26, ‐0.23] |
3.1 Normal renal function |
6 |
313 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.31 [‐0.57, ‐0.04] |
3.2 Renal disease requiring dialysis |
2 |
57 |
Std. Mean Difference (IV, Random, 95% CI) |
‐2.18 [‐3.31, ‐1.06] |
4 Restlessness, Subgroup ‐ iron status at baseline |
8 |
370 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐1.26, ‐0.23] |
4.1 Low or low‐normal baseline iron stores |
3 |
188 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.37 [‐0.81, 0.07] |
4.2 Unselected for baseline iron measures |
5 |
182 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.95 [‐1.85, ‐0.06] |
5 Restlessness, Subgroup ‐ intravenous versus oral iron |
8 |
370 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐1.26, ‐0.23] |
5.1 Oral iron |
1 |
18 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.29 [‐2.35, ‐0.23] |
5.2 Intravenous iron |
7 |
352 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.68 [‐1.23, ‐0.14] |
6 Restlessness, Subgroup ‐ iron sucrose versus ferric carboxymaltose |
6 |
327 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.55 [‐1.09, 0.00] |
6.1 Iron sucrose |
3 |
110 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.88 [‐2.48, 0.72] |
6.2 Ferric carboxymaltose |
3 |
217 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.31 [‐0.57, ‐0.04] |
7 Restlessness, Sensitivity analysis ‐ excluding studies at high risk of bias |
7 |
338 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.46 [‐0.82, ‐0.10] |
8 Quality of life (dichotomous measure) |
2 |
39 |
Risk Ratio (M‐H, Random, 95% CI) |
2.01 [0.54, 7.45] |
9 Change in quality of life (continuous measure) |
3 |
128 |
Std. Mean Difference (IV, Random, 95% CI) |
0.51 [0.15, 0.87] |
10 Withdrew to use other RLS medication or because of inadequate RLS symptom control |
9 |
391 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.41, 1.47] |
11 Change in subjective sleep quality |
3 |
128 |
Std. Mean Difference (IV, Random, 95% CI) |
0.19 [‐0.18, 0.56] |
12 Change in PLMS |
2 |
60 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.19 [‐0.70, 0.32] |
13 Adverse events |
6 |
298 |
Risk Ratio (M‐H, Random, 95% CI) |
1.48 [0.97, 2.25] |
14 Gastrointestinal side effects |
8 |
380 |
Risk Ratio (M‐H, Random, 95% CI) |
1.44 [0.76, 2.75] |
15 Drop out due to adverse event |
9 |
398 |
Risk Ratio (M‐H, Random, 95% CI) |
1.91 [0.50, 7.26] |